Citizens Rates Kura Oncology (KURA) buy, $24 Price Target
Citizens continues to see upside in KURA, maintaining a buy rating and setting a $24 price target.
Reviewed by automated data checks against the source data. How we make and check alerts
Citizens rated Kura Oncology, Inc. ($KURA) "buy" with a $24 price target on June 15, 2026.
Since the rating, $KURA is up 8.6% after 1 week, up 18.8% after 1 month and down 4.8% to date (from the $9.54 close on Jun 15, 2026).
KURA
Kura Oncology, Inc.
Key Points
- On June 15, 2026, Citizens reiterated its buy rating on KURA, setting a price target of $24.
- KURA shares are trading around $9.05, showing potential for significant upside according to analysts.
- Recent insider buying and institutional activity indicate growing interest in KURA stock.
Get $KURA trade alerts by text
We text you when insiders, Congress or big funds trade $KURA. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Kura Oncology, Inc. alert may contain errors. Disclosures
On June 15, 2026, Citizens reiterated its buy rating for KURA, setting a price target of $24. The stock is currently trading at about $9.05, suggesting potential upside if the target is reached.
Other Institutional Activity in KURA
Several institutional investors have recently adjusted their positions in KURA. BlackRock, Inc. increased its stake by 626,738 shares, bringing its total to 9,637,531 shares valued at approximately $78.3 million. Suvretta Capital Management, LLC maintained its holdings at 8,575,422 shares worth about $69.7 million. BVF Inc/IL reduced its position by 171,393 shares, holding 8,445,769 shares valued at $68.7 million. State Street Corp decreased its stake by 419,199 shares, now holding 4,511,891 shares worth $36.7 million. Meanwhile, Vanguard Capital Management LLC initiated a new position with 3,785,685 shares valued at $30.8 million.
Kura Oncology, Inc. Stock Down 22.8%
KURA shares are trading near $9.05. The stock has caught the attention of analysts and investors alike, with several institutions adjusting their holdings and analysts maintaining optimistic price targets.
$KURA price target
Kura Oncology, Inc. daily closes and this analyst's $24 target. Not advice.
Insider Buying and Selling at Kura Oncology, Inc.
In a notable show of confidence, several insiders purchased shares on June 4, 2026. Thomas Malley, Faheem Hasnain, Helen Louise Collins, Carol Schafer, Michael Vasconcellos, and Mary Szela each bought 35,000 shares. These transactions were not part of any pre-planned trading plan.
Analysts Set New Price Targets
On June 15, 2026, Citizens reiterated its buy rating for KURA with a $24 price target. Other analysts have also shown optimism. Lake Street initiated coverage with a buy rating and a $23 target on April 14, 2026. Mizuho maintained its buy rating on March 24, 2026, with a $25 target. UBS and Wedbush also maintained buy ratings with targets of $15 and $36, respectively.
About KURA
KURA is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company is committed to advancing its pipeline of targeted drugs to improve the lives of patients with serious diseases.
Bottom Line
Citizens' reiterated buy rating and $24 price target for KURA underscore the potential seen in the company's future performance. The stock's current price and recent insider buying suggest strong interest and confidence in KURA's prospects. As always, these analyst ratings are based on past data and expectations, and investors should consider the full range of information available.
Related Filing Alerts
Source: Citizens's rating change on $KURA (Jun 15, 2026). Written by software, not financial advice. How we make alerts